



Selected opportunities in Cardiovascular diseases

Predicting the survival time of patients suffering of Myocardial Infarction or its recurrence (BIO13036)

Cardiovascular Opportunity – June 2018 – sylvestre.chea@insermtransfert.fr



PREDICTING THE SURVIVAL TIME OF PATIENTS SUFFERING OF MYOCARDIAL INFARCTION OR ITS RECURRENCE (BIO13036)

duct factsheet			Stage: Pre-Analytic Validation
Biomarker:	Technology:	Information:	
 BAFF 	 ELISA, IHC, Flow Cytometry 	 Prognosis 	
	Sample:		
Scientific and Clinica	I Rationale:		
 Mature B lymphocyt adverse ventricular inflammatory response 	es are recruited to the ischemic tissue after myocardi remodeling and improves cardiac function after acut ses after acute MI, impairs monocyte mobilization.	al infarction. B lymphocyte e MI, reduces both syste	e depletion prever emic and local p
 The cytokine BAFF is important role in the 	expressed in myeloid and lymphoid B cell lineage cells, a proliferation and differentiation of B cells.	nd acts as a potent B cell a	ctivator and plays
► POC:			
 POC in human (1000) 	patients admitted for acute MI) and animal models		
 In a cohort of 1000 pa with adverse cardiova 	atients admitted for acute myocardial infarction, the circu scular outcome.	lating level of BAFF is eleva	ted and is associat
Selling points:			
Patent:			
 EP13 305 299.3 on 	2013/03/15		
PCT/EP2014/05505	9 on 2014/03/14		
 Granted: US 			
 Scientific Publication 	(s):		
 <u>Nat Med</u>, 2013 Oct 	ober, <i>Zouggari Y. et al.,</i> doi: 10.1038/nm.3284		

• Sci Rep, 2017 Jun 23, Ponnuswamy P. et al., doi: 10.1038/s41598-017-04438-6

Cardiovascular Opportunity – June 2018 – sylvestre.chea@inserm-transfert.fr

Insermirat

2

PREDICTING THE SURVIVAL TIME OF PATIENTS SUFFERING OF MYOCARDIAL INFARCTION OR ITS RECURRENCE (BIO13036)

Proof of concept



Cardiovascular Opportunity – June 2018 – sylvestre.chea@inserm-transfert.fr 3